ERBB2 and neoplasm: These effector cells recognized autologous HER2-positive GBMs including their CD133-positive stem cells in vitro and had potent anti-tumor activity against both killed CD133-positive and CD133-negative cells derived from primary HER2-positive GBMs (80).